Physician profile
Greg A Warren
NPI 1245270131
$3,148.06
in general payments reported to CMS, 2019-2025
25 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $356 · 2021: $272 · 2022: $399 · 2023: $274 · 2024: $501 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265 · Education: $38.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.61 |
| Education | $38.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $577.24 | 2019-2025 | Jynarque |
| Amgen INC. | $407.45 | 2019-2024 | Tavneos, Aranesp, Parsabiv |
| Astrazeneca Pharmaceuticals Lp | $329.24 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $184.58 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $180.95 | 2021-2025 | |
| Ardelyx, INC. | $175.66 | 2024-2025 | Ibsrela |
| Mallinckrodt Enterprises LLC | $160.03 | 2019 | |
| Akebia Therapeutics INC | $146.54 | 2019-2024 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $141.01 | 2019-2022 | |
| Vifor Pharma, INC. | $138.54 | 2019-2025 | Veltassa |
| Aurinia Pharma U.S., INC. | $126.90 | 2021-2025 | Lupkynis |
| Novo Nordisk INC | $110.21 | 2019-2025 | Ozempic, Wegovy |
| Calliditas Therapeutics US INC. | $86.82 | 2022-2023 | Tarpeyo |
| Baxter Healthcare | $85.25 | 2019 | |
| Glaxosmithkline, LLC. | $65.36 | 2022-2023 | Benlysta, Jesduvroq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $48.70 | 2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.32 | 2023-2025 | Jardiance |
| Abbott Laboratories | $35.14 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.01 | 2024 | |
| Travere Therapeutics, INC. | $17.98 | 2024 | |
| Becton, Dickinson and Company | $17.14 | 2025 | Venovo |
| Teleflex LLC | $15.86 | 2023 | Arrow |
| Ani Pharmaceuticals, INC. | $15.10 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.08 | 2019 | |
| Genzyme Corporation | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.